3/14
08:04 am
lyra
Lyra Therapeutics, Inc. (NASDAQ: LYRA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Medium
Report
Lyra Therapeutics, Inc. (NASDAQ: LYRA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.